secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jaguar Health, Inc. (JAGX)
CIK:        0001585608
Form:       8-K
Filed at:   2026-05-20T20:36:22+00:00
Accession:  0001193125-26-232722
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jaguar Health Q1 revenue up 816% to $20.3M on $19M license deal; net loss narrows to $7.0M
--------------------------------------------------------------------------------

- Total revenue $20.3M (816% YoY increase) driven by $19.1M license revenue from Woodward/Future Pak deal.
- Product revenue $1.2M, down 45% YoY; Mytesi/Canalevia-CA1 rights licensed to Future Pak in Jan 2026.
- Net loss attributable to common stockholders $7.0M, improved 33% from $10.5M loss in Q1 2025.
- Non-GAAP recurring EBITDA loss $5.1M, improved 48% from $9.7M loss a year ago.
- Company to present crofelemer data for rare-disease intestinal failure at ESPGHAN June 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1585608/000119312526232722/0001193125-26-232722-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1585608/000119312526232722/d143790d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-232722

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer